HB 2749 — An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.
Last action — Referred to Health
-
✓Introduced
-
2In Committee
-
3Passed House
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill is in committee in the House. Introduced August 25, 2026. It must pass committee before a floor vote.
Next likely step: a committee vote, then a floor vote in the House.
Odds of enactment
Low chanceBased on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
In Committee
Current position in the legislative process.
-
5 sponsors
1 primary, 4 co-sponsors signed on.
-
Single-party support
Sponsorship is currently within one party (5 D).
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
In plain language
This bill amends regulations regarding drug overdose medication.
The bill updates provisions in The Controlled Substance, Drug, Device and Cosmetic Act related to drug overdose medication. It aims to enhance the existing framework for handling such medications.
Bill Text
- Printer's No. PN3839 View text Current pdf
AI-generated reading aid from the bill's amendatory text — verify against the official bill.
The bill expands liability protections related to the prescribing and administration of opioid antagonists, including expired ones, to various entities and individuals.
-
Section 13.8(e)
(2) The immunity under paragraph (1) shall not apply to a health professional who acts with intent to harm or with reckless indifference to a substantial risk of harm.
This addition clarifies that immunity from liability does not apply if the health professional acts with harmful intent or reckless indifference.
-
Section 13.8(f)
(f.1) A municipality, local health department or community-based organization that provides or distributes an expired opioid antagonist shall not be subject to any criminal or civil liability for: (1) the dispensing or provision of the expired opioid antagonist under this section; or (2) any outcomes resulting from the eventual administration of the expired opioid antagonist.
This new subsection grants liability protection to municipalities and organizations for distributing expired opioid antagonists.
-
Section 13.8(f)(2)
Receipt of training and instructional materials that meet the criteria of subsection (a) and the prompt seeking of additional medical assistance shall create a rebuttable presumption that the person acted with reasonable care in administering an opioid antagonist.This strikes the specific presumption of reasonable care related to training and seeking medical assistance.
-
Section 13.8(h)
[term "opioid antagonist" means a]→ following words and phrases shall have the meanings given to them in this subsection unless the context clearly indicates otherwise:This change clarifies the definitions provided in the section, initially stating them as a term definition.
-
Section 13.8(h)
"Expired opioid antagonist" means an opioid antagonist that has an expiration date that is less than five years from the date of use.
This defines expired opioid antagonists for legal and regulatory clarity.
-
Section 13.8(h)
"Municipality" means a city, borough, incorporated town or township.
This defines what constitutes a municipality in the context of the legislation.
-
Section 13.8(h)
"Opioid antagonist" means a drug or device approved by the Federal Food, Drug, and Cosmetic Act (52 Stat. 1040, 21 U.S.C. § 301 et seq.) for emergency reversal of known or suspected opioid overdose, including naloxone hydrochloride or other similarly acting drugs approved by the United States Food and Drug Administration for the treatment of an opioid overdose.
This redefines opioid antagonist for clarity in terms of approved substances.
Action History
-
Referred to Health
Sponsors
- Dan K. Williams · Cosponsor
- Benjamin V. Sanchez · Cosponsor
- Lindsay Powell · Cosponsor
- Ben Waxman · Cosponsor
- Liz Hanbidge · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 4 co-sponsors · 248 not signed on
Sponsors (1)
- Liz Hanbidge Democratic
Co-sponsors (4)
- Dan K. Williams Democratic
- Benjamin V. Sanchez Democratic
- Lindsay Powell Democratic
- Ben Waxman Democratic
Not signed on (248)
248 members have not signed on to this bill.
Show all 248 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- Who sponsors HB 2749?
- HB 2749 is sponsored by Dan K. Williams (Democratic), Benjamin V. Sanchez (Democratic), Lindsay Powell (Democratic), Ben Waxman (Democratic), and Liz Hanbidge (Democratic).
- What is the current status of HB 2749?
- This bill is in committee in the House. Introduced August 25, 2026. It must pass committee before a floor vote.
- Where can I track HB 2749?
- Track HB 2749 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HB 2749
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HB 2749
Last checked for changes about 1 month ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →